跳轉至內容
Merck
全部照片(1)

Key Documents

53324-U

Supelco

Ascentis® Express Peptide 160 Å ES-C18 (2.7 μm) HPLC Columns

L × I.D. 10 cm × 4.6 mm, HPLC Column

登入查看組織和合約定價


About This Item

分類程式碼代碼:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Ascentis® Express Peptide ES-C18, 2.7μm HPLC 色谱柱, 2.7 μm particle size, L × I.D. 10 cm × 4.6 mm

材料

stainless steel column

品質等級

agency

suitable for USP L1

產品線

Ascentis®

特點

endcapped: no

製造商/商標名

Ascentis®

包裝

1 ea of

參數

≤100 °C temp. range
600 bar max. pressure (9000 psi)

技術

HPLC: suitable
LC/MS: suitable
UHPLC-MS: suitable
UHPLC: suitable

長度 × 內徑

10 cm × 4.6 mm

表面積

90 m2/g

雜質

<5 ppm metals

基質

Fused-Core particle platform
superficially porous particle

基質活性組

C18 (octadecyl) phase

粒徑

2.7 μm

孔徑

160 Å

工作pH值範圍

1-9

分離技術

reversed phase

尋找類似的產品? 前往 產品比較指南

相關類別

一般說明

Ascentis Express Peptide ES-C18 色谱柱是专为分离肽和小分子蛋白等高分子量化合物而设计的。这些色谱柱含有先进的熔融核心颗粒,这些颗粒具有较大的孔隙(标准 Ascentis Express 中的 160Å与 90Å),与立体保护的 C18 配体结合,以提供极低 pH 值 (<1) 和高温(高达 100ºC)下的额外稳定性 (ES)。这大大扩展了 Ascentis Express 色谱柱的应用范围。

法律資訊

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Meiyun Shi et al.
Journal of separation science, 38(8), 1351-1357 (2015-01-30)
The pentapeptide thymopentin (Arg-Lys-Asp-Val-Tyr, RKDVY) corresponds to amino acids 32-36 of the 49 amino acid immunomodulatory polypeptide, thymopoietin, whose biological activity is partially reproduced. Thymopentin is widely used in the clinic and represents a promising target for drug design but
E Lesellier
Journal of chromatography. A, 1266, 34-42 (2012-11-03)
The recent introduction of new stationary phases for liquid chromatography based on superficially porous particles, called core-shell or fused-core, dramatically improved the separation performances through very high efficiency, due mainly to reduced eddy diffusion. However, few studies have evaluated the
C Gröer et al.
Journal of pharmaceutical and biomedical analysis, 100, 393-401 (2014-09-15)
Cytochrome P450 (CYP) enzymes and UDP-glucuronosyltransferases (UGT) are major determinants in the pharmacokinetics of most drugs on the market. To investigate their impact on intestinal and hepatic drug metabolism, we developed and validated quantification methods for nine CYP (CYP1A2, CYP2B6

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務